Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics

Viking Therapeutics

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so.

Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge

Coupang

Microsoft

NVIDIA

Stanley Druckenmiller has one of the best investing records out there. He worked closely with George Soros, helping to "break the Bank of England.

Nearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks

Eaton

Coca-Cola

Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.

These 3 Companies Recently Lifted Guidance

Eli Lilly's non-GAAP earnings of $2.58 per share surpassed analysts' estimates. Revenue increased by 26% year over year, but still fell just short of analysts' expectations.

Eli Lilly's Q1: Another Quarter of Strong Growth

Eli Lilly and Company (NYSE:LLY ) Q1 2024 Earnings Conference Call April 30, 2024 10:00 AM ET Company Participants Joe Fletcher – Senior Vice President-Investor Relations Dave Ricks – Chief Executive Officer Anat Ashkenazi – Chief Financial Officer Dan Skovronsky – Chief Scientific Officer and President-Lilly Immunology Anne White – President-Lilly Neuroscience Jake Van Naarden – President-Loxo Patrik Jonsson – President-Lilly Diabetes and Obesity and Lilly USA Conference Call Participants Chris Schott – JPMorgan Mohit Bansal – Wells Fargo Umer Raffat – Evercore Seamus Fernandez – Guggenheim Tim Anderson – Wolfe Research Terence Flynn – Morgan Stanley Akash Tewari – Jefferies Trung Huynh – UBS Geoff Meacham – Bank of America Kerry Holford – Berenberg Steve Scala – TD Cowen Evan Seigerman – BMO Capital Markets David Risinger – Leerink Partners Louise Chen – Cantor Chris Shibutani – Goldman Sachs Carter Gould – Barclays Kripa Devarakonda – Truist Securities James Shin – Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2024 Earnings Call. At this time all participants are in a listen-only mode.

Eli Lilly and Company (LLY) Q1 2024 Earnings Call Transcript

Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised

Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.

Eli Lilly Stock Surges on Demand for Weight-Loss Drugs

Lilly missed Wall Street's revenue estimate for the first quarter. However, the drugmaker easily beat the consensus Q1 earnings estimate.

Why Eli Lilly Stock Is Jumping Today

The Eli Lilly And Company (NYSE: LLY) stock has jumped +53.33 (7.23%) after the company reported strong financial performance in its Q1 earnings report. At press time, the Eli Lilly stock was trading at $790.50 up from yesterday's close of $737.17.

Eli Lilly (LLY) stock soars, Q1 earnings results show 26% revenue growth

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Lilly (LLY) Reports Q1 Earnings: What Key Metrics Have to Say

Stocks are lower across the board  today, but don't blame Eli Lilly And Co (NYSE:LLY) and 3M Co (NYSE:MMM).

2 Stocks Surging After Earnings This Morning

Eli Lilly (LLY) stock jumped in early trading Tuesday after the drugmaker reported first-quarter earnings that beat analysts' expectations and raised its guidance thanks to continued high demand for the company's weight-loss drugs.

Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth

Eli Lilly (LLY) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.53 per share. This compares to earnings of $1.62 per share a year ago.

Eli Lilly (LLY) Tops Q1 Earnings Estimates

Eli Lilly and Co (NYSE:LLY)'s weight loss medication Mounjaro drove impressive first-quarter earnings results for the US pharmaceuticals megacap. Mounjaro generated worldwide revenue of $1.81 billion in the three-month period, representing an increase from $568.5 million in the first quarter of 2023.

Mounjaro drives Eli Lilly sales skyward, shares near all-time high

Eli Lilly earnings beat but sales missed, despite strong demand of weight-loss drug Zepbound. The drug giant guided up.

Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat

The pharmaceutical company reported adjusted earnings of $2.58 a share for the first quarter of 2024, up 59% from the same period a year earlier. Revenue rose 26% to $8.77 billion.

Eli Lilly Stock Jumps After Earnings Beat. Weight-Loss Drugs Are Driving Gains.

Eli Lilly & Co. shares gained more than 5% premarket on Tuesday after the company reported first-quarter profit that topped analyst expectations amid strong sales of diabetes drug Mounjaro and weight-loss treatment Zepbound. The drugmaker reported net income of $2.243 billion, or $2.48 per share, up from $1.345 billion, or $1.49 per share, in the year-earlier period.

Eli Lilly's stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro, Zepbound

Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.

Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro

Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro.

Eli Lilly lifts profit view on diabetes and weight-loss drug strength

Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's disease in the U.S. and EU; resubmission of lebrikizumab for atopic dermatitis in the U.S.; and initiation of lepodisiran in a Phase 3 study for atherosclerotic cardiovascular disease.

Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum

Eli Lilly's tirzepatide aced a pair of clinical trials. The medicine's sales potential looks mouthwatering.

Eli Lilly Just Announced More Good News: Time to Buy?

Novo Nordisk

UnitedHealth Group

Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs that can help diabetes and obesity, two significant health concerns around the world.

Forget Nvidia, These Unstoppable Stocks Are Better Buys

Eli Lilly is the developer of GLP-1 treatments Mounjaro and Zepbound. Currently used to treat diabetes and obesity, they could have far more reach.

1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

AbbVie

Pfizer

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

News for Eli Lilly Stock (LLY)